Rap Icon Nelly Joins the Kinexions 2025 Lineup
Kinaxis announces multi-platinum-selling music artist will take center stage at the premier supply chain community event of the year
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that Nelly will be headlining the entertainment stage at Kinexions 2025, its annual supply chain community conference taking place in Austin, Texas from March 31 to April 2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219302821/en/
Multi-platinum-selling rap icon Nelly will take center stage at Kinexions 2025, the premier supply chain community event of the year. (Photo: Business Wire)
Nelly is one of the best-selling rappers of all time: he's sold more than 21 million albums, he’s won multiple Grammys and Billboard Music Awards, and his 2000 debut Country Grammar is one of the only hip-hop albums in history to have gone 10 times platinum. Kinexions has previously featured Flo Rida, The Brothers Osborne, Melissa Etheridge, Serena Ryder and others at its community celebration event.
Kinaxis customers ExxonMobil, Eaton, Volvo Cars, Colgate-Palmolive, Merck & Co, General Motors, National Instruments, and Schneider Electric will be presenting at the 2025 conference, as well as mainstage keynote presenter Barbara Corcoran of Shark Tank fame.
“In addition to the great line-up of the best supply chain brains in the business, and one of the world’s foremost entrepreneurs and investors, we’re thrilled to welcome a superstar like Nelly,” saidAndrew Bell, chief product officer at Kinaxis. “The three-day event promises tons of innovation and networking opportunities and having a musical icon of Nelly’s stature makes Kinexions 2025 truly unmissable.”
Kinexions 2025 is made possible by its platinum sponsors Accenture, Capgemini and Scott Sheldon; and gold sponsors 4flow, Genpact, Microsoft, Google Cloud and Spinnaker SCA.Registration for Kinexions 2025 is open at www.kinexions.com.
To learn more about Kinaxis and its supply chain orchestration solutions, please visit www.kinaxis.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219302821/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 12:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 HighlightsTotal revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inco
SINOVAC Announces New Board Member and Chairman of the Audit Committee28.3.2025 12:00:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed funds have been shareholders of SINOVAC since 2013 and currently hold over 2.7 million shares. Following this appo
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX1128.3.2025 11:00:00 CET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328881021/en/ The submission was based on a multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early-stage, o
European DataWarehouse is Awarded Data Provider of the Year for the Fifth Time28.3.2025 08:46:00 CET | Press release
European DataWarehouse (EDW) is pleased to announce it was named Data Provider of the Year at the 2025 GlobalCapital European Securitization Awards in London. The award ceremony recognises the outstanding achievements in European structured finance and winners are selected by popular vote from industry participants. As defined by GlobalCapital, the program celebrates “the very best in the market, as chosen by the market”. This is the fifth time that EDW has won the prestigious Data Provider of the Year award, having also been awarded the honour in 2019, 2022, 2023 and 2024! Dr. Christian Thun, CEO of EDW, stated: “Receiving this award for the fifth time is a testament to the trust and recognition our team has earned within the European securitisation market. This achievement highlights our ongoing commitment to excellence and industry leadership.” Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “EDW continues to stand as a trusted partner in the securitisation mark
W. R. Berkley Corporation Confirms Mitsui Sumitomo Insurance Co. Intends to Purchase 15% of the Company’s Shares in Open Market or Private Transactions From Third Parties28.3.2025 07:48:00 CET | Press release
MSI also entered into a voting arrangement with a company that is owned by the Berkley family and trusts for their benefit, which holds approximately 16% of the Company’s outstanding Common Stock W. R. Berkley Corporation (NYSE: WRB) (the “Company”) today confirmed that Mitsui Sumitomo Insurance Co., Ltd. (“MSI”), a leading Japanese property and casualty insurance carrier, has entered into an arrangement (the “Investment and Voting Arrangement”) with a company owned by members of the Berkley family and trusts for their benefit (collectively, the “Berkley Family”) providing for MSI to purchase 15% of the Company’s outstanding common stock (the “Common Stock”) through open market purchases or private transactions with third parties. The Berkley Family will not be selling any of its Common Stock to MSI, nor will MSI be purchasing any shares from the Company as part of the arrangement. Under the terms of the agreements being entered into between MSI and the Berkley Family, once MSI acquire
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom